News Releases Year None20242023202220212020201920182017 NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer Mar 04, 2020 NuCana to Present at the Cowen and Company 40th Annual Health Care Conference Feb 25, 2020 NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Jan 27, 2020 NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference Nov 26, 2019 NuCana to Present at the Jefferies 2019 London Healthcare Conference Nov 14, 2019 NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update Nov 13, 2019 NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct 29, 2019 NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Oct 25, 2019 NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference Aug 29, 2019 NuCana to Participate in Citi’s 14th Annual Biotech Conference Aug 27, 2019 Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 Next page next › Last page last »
NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer Mar 04, 2020
NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Jan 27, 2020
NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct 29, 2019
NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Oct 25, 2019